Topical IL-1-Ra for Treatment of Corneal Neovascularization

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Corneal Neovascularization

In brief

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.

Key facts

Study ID

NCT00915590

Run by

Reza Dana, MD

People needed

10

Starts

2009-04-01

Expected to finish

2011-03-01

Last updated by the study team

2017-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age > 18 years
• Patients with superficial or deep corneal NV that extends farther than 1 mm from the limbus
• Patients are in generally good stable overall healthExclusion Criteria: • Has received treatment with anti-VEGF agents (topical, intraocular or systemic) within 30 days of study entry
• Corneal or ocular surface infection within 30 days prior to study entry• Ocular or periocular malignancy
• Contact lens (excluding bandage contact lens) use within 2 weeks prior to study entry
• Persistent epithelial defect (>1mm and ≥14 days duration) within 2 weeks prior to study entry
• Intravitreal or periocular steroids within 2 weeks prior to study entry
• Change in dose/frequency of topical steroids and/or NSAIDs within 2 weeks prior to study entry
• Pregnancy (positive pregnancy test) or lactation
• Premenopausal women not using contraception
• Signs of current infection, including fever and current treatment with antibiotics
• Participation in another simultaneous medical investigation or trial

Where it is running

• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.